Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

1.0K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.0K
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

37.7K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
37.7K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

858
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
858
Liver Physiology01:30

Liver Physiology

4.2K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
4.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

249
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
249

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.

Clinics in liver disease·2026
Same author

Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4α.

JHEP reports : innovation in hepatology·2026
Same author

Association of Statin Use with Reduced Primary Liver Cancer Risk, Independent of Age and Cirrhosis Protection in MASLD.

Cancers·2026
Same author

Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Hepatology (Baltimore, Md.)·2026
Same author

Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis.

JHEP reports : innovation in hepatology·2026
Same author

Age and sex influence transcriptomic responses to statin therapy that control liver aging during systemic metabolic dysfunction.

Hepatology (Baltimore, Md.)·2026

Related Experiment Video

Updated: Mar 21, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.9K

Nonalcoholic Fatty Liver Disease.

Tyler Thrasher1, Manal F Abdelmalek2

  • 1clinical trials assistant, Division of Gastroenterology and Hepatology, Department of Medicine, Duke University, Durham, North Carolina.

North Carolina Medical Journal
|May 8, 2016
PubMed
Summary

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease. Research is ongoing for noninvasive biomarkers and effective treatments for nonalcoholic steatohepatitis (NASH).

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

2.0K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

7.9K

Related Experiment Videos

Last Updated: Mar 21, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.9K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

2.0K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

7.9K

Area of Science:

  • Hepatology
  • Metabolic Syndrome
  • Liver Disease Research

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is the primary hepatic manifestation of metabolic syndrome.
  • It represents the leading cause of chronic liver disease globally.
  • Current management strategies focus on lifestyle changes and addressing associated risk factors.

Purpose of the Study:

  • To investigate noninvasive biomarkers for the diagnosis and staging of NAFLD.
  • To explore safe and cost-effective therapeutic options for nonalcoholic steatohepatitis (NASH) and related cirrhosis.

Main Methods:

  • Biomarker discovery and validation studies.
  • Clinical trials for novel therapeutic agents.
  • Epidemiological research on NAFLD prevalence and progression.

Main Results:

  • Ongoing investigation into novel diagnostic and staging biomarkers.
  • Development and evaluation of potential treatments for NASH.
  • Identification of key risk factors contributing to NAFLD progression.

Conclusions:

  • There is a critical need for improved diagnostic tools for NAFLD.
  • Development of effective treatments for NASH and its complications is a priority.
  • Further research is essential to combat the growing burden of NAFLD.